scholarly journals Association of high-sensitivity C-reactive protein with de novo major depression

2010 ◽  
Vol 197 (5) ◽  
pp. 372-377 ◽  
Author(s):  
Julie A. Pasco ◽  
Geoffrey C. Nicholson ◽  
Lana J. Williams ◽  
Felice N. Jacka ◽  
Margaret J. Henry ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
De Novo ◽  
High Sensitivity ◽  
Prior History ◽  
C Reactive Protein ◽  
Major Depressive ◽  
Standard Deviation Increase ◽  
Reactive Protein ◽  
Increased Risk

BackgroundAlthough there is cross-sectional evidence that changes in the immune system contribute to the pathophysiology of depression, longitudinal data capable of elucidating cause and effect relationships are lacking.AimsWe aimed to determine whether subclinical systemic inflammation, as measured by serum high-sensitivity C-reactive protein (hsCRP) concentration, is associated with an increased risk of de novo major depressive disorder.MethodMajor depressive disorder was diagnosed using a clinical interview (SCID–I/NP). This is a retrospective cohort study; from a population-based sample of 1494 randomly selected women recruited at baseline during the period 1994–7, 822 were followed for a decade and provided measures of both exposure and outcome. Of these women, 644 (aged 20–84 years) had no prior history of depression at baseline and were eligible for analysis.ResultsDuring 5827 person-years of follow-up, 48 cases of de novo major depressive disorder were identified. The hazard ratio (HR) for depression increased by 44% for each standard deviation increase in log-transformed hsCRP (ln-hsCRP) (HR = 1.44, 95% CI 1.04–1.99), after adjusting for weight, smoking and use of non-steroidal anti-inflammatory drugs. Further adjustment for other lifestyle factors, medications and comorbidity failed to explain the observed increased risk for depression.ConclusionsSerum hsCRP is an independent risk marker for de novo major depressive disorder in women. This supports an aetiological role for inflammatory activity in the pathophysiology of depression.

scholarly journals C-reactive protein and clinical subtypes of major depressive disorder at Zagazig University Hospitals

2020 ◽  
Vol 27 (1) ◽  
Author(s):  
Amany Elshabrawy Mohamed ◽  
Rafik Reda Abd El-Latif ◽  
Amira Mohamed Youssef ◽  
Abdallah Saad Ibrahim
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
C Reactive Protein ◽  
University Hospitals ◽  
Major Depressive ◽  
Reactive Protein

C-reactive protein: A differential biomarker for major depressive disorder and bipolar II disorder

2016 ◽  
Vol 18 (1) ◽  
pp. 63-70 ◽  
Author(s):  
Hui Hua Chang ◽  
Tzu-Yun Wang ◽  
I Hui Lee ◽  
Sheng-Yu Lee ◽  
Kao Chin Chen ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Protein A ◽  
C Reactive Protein ◽  
Major Depressive ◽  
Bipolar Ii Disorder ◽  
Reactive Protein ◽  
Bipolar Ii

Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice

CNS Spectrums ◽  
2016 ◽  
Vol 22 (4) ◽  
pp. 342-347 ◽  
Author(s):  
Domenico De Berardis ◽  
Michele Fornaro ◽  
Laura Orsolini ◽  
Felice Iasevoli ◽  
Carmine Tomasetti ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Clinical Practice ◽  
Depressive Symptoms ◽  
Depressive Disorder ◽  
Real World ◽  
Level Variation ◽  
C Reactive Protein ◽  
Major Depressive ◽  
Everyday Clinical Practice ◽  
Reactive Protein

ObjectiveAgomelatine is a newer antidepressant but, to date, no studies have been carried out investigating its effects on C-reactive protein (CRP) levels in major depressive disorder (MDD) before and after treatment. The present study aimed (i) to investigate the effects of agomelatine treatment on CRP levels in a sample of patients with MDD and (ii) to investigate if CRP variations were correlated with clinical improvement in such patients.Methods30 adult outpatients (12 males, 18 females) with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of MDD were recruited in “real-world,” everyday clinical practice and treated with a flexible dose of agomelatine for 12 weeks. The Hamilton Rating Scale for Depression (HAM-D) and the Snaith-Hamilton Pleasure Scale (SHAPS) were used to evaluate depressive symptoms and anhedonia, respectively. Moreover, serum CRP was measured at baseline and after 12 weeks of treatment.ResultsAgomelatine was effective in the treatment of MDD, with a significant reduction in HAM-D and SHAPS scores from baseline to endpoint. CRP levels were reduced in the whole sample, with remitters showing a significant difference in CRP levels after 12 weeks of agomelatine. A multivariate stepwise linear regression analysis showed that higher CRP level variation was associated with higher baseline HAM-D scores, controlling for age, gender, smoking, BMI, and agomelatine dose.ConclusionsAgomelatine’s antidepressant properties were associated with a reduction in circulating CRP levels in MDD patients who achieved remission after 12 weeks of treatment. Moreover, more prominent CRP level variation was associated with more severe depressive symptoms at baseline.

scholarly journals Adiposity, depression and anxiety: interrelationship and possible mediators

2019 ◽  
Vol 53 ◽  
pp. 103 ◽  
Author(s):  
Ana Paula Gomes ◽  
Ana Luiza G. Soares ◽  
Ana M.B. Menezes ◽  
Maria Cecília Assunção ◽  
Fernando C. Wehrmeister ◽  
...  
Keyword(s):  
Physical Activity ◽  
Major Depressive Disorder ◽  
Anxiety Disorder ◽  
Depressive Disorder ◽  
Generalized Anxiety Disorder ◽  
Diet Quality ◽  
Generalized Anxiety ◽  
C Reactive Protein ◽  
Major Depressive ◽  
Reactive Protein

OBJECTIVES: To explore the association between adiposity, major depressive disorder and generalized anxiety disorder, and to assess the role of inflammation, diet quality and physical activity in this association. METHODS: We used data from 2,977 individuals from the 1993 Pelotas Cohort (Brazil) who attended the 18- and 22-year follow-ups. We assessed general obesity using body mass index, fat mass index, and abdominal obesity using waist circumference. Major Depressive Disorder and generalized anxiety disorder were assessed using the mini-international neuropsychiatric interview. C-reactive protein and interleukin-6 (IL-6) levels were used as a measure of inflammation; diet quality was estimated using the revised diet quality index, and physical activity was assessed by the International physical activity questionnaire (IPAQ, min/day). The association between adiposity and major depressive disorder and generalized anxiety disorder was assessed using logistic regression, and the natural indirect effect via the mediators was estimated using G-computation. RESULTS: General obesity assessed by body mass index (OR: 2.3; 95% CI:1.13; 4.85), fat mass index (OR: 2.6; 95%CI: 1.37; 4.83), and abdominal obesity (OR: 2.5; 95%CI: 1.18; 5.39) were associated with higher odds of major depressive disorder, whereas major depressive disorder was only associated with obesity assessed by body mass index (OR=1.9; 95% CI: 1.09; 3.46). Obesity and generalized anxiety disorder were not associated. C-reactive protein, diet quality and physical activity did not mediate the effect of obesity on major depressive disorder, and C-reactive protein mediated about 25% of the effect of major depressive disorder on adiposity. CONCLUSIONS: Depression, but not generalized anxiety disorder, is associated with adiposity in both directions, with a stronger evidence for the direction obesity-depression. Inflammation explains part of the effect of major depressive disorder on obesity but not the other way around. Further research should explore other mechanisms that could be involved in the association between obesity and depression.

Sign in / Sign up

Export Citation Format

Share Document